Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 15.12.2012 | EN | Official Journal of the European Union | C 389/5 |

---

Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 3 October 2012 — Actavis Group PTC EHF, Actavis UK Ltd v Sanofi

(Case C-443/12)

2012/C 389/07

Language of the case: English

Referring court

High Court of Justice (Chancery Division)

Parties to the main proceedings

Applicants: Actavis Group PTC EHF, Actavis UK Ltd

Defendant: Sanofi

Third party: Sanofi Pharma Bristol-Myers Squibb SNC

Questions referred

|  |  |
| --- | --- |
| 1. | What are the criteria for deciding whether ‘the product is protected by a basic patent in force’ in Article 3(a) of Regulation 469/2009/EC[(1)](#ntr1-C_2012389EN.01000501-E0001) (‘the Regulation’)? |

|  |  |
| --- | --- |
| 2. | In a situation in which multiple products are protected by a basic patent in force, does the Regulation, and in particular Article 3(c), preclude the proprietor of the patent being issued a certificate for each of the products protected? |

---

[Top](#document1)